Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas

NCT00620607 is registered in ClinicalTrials.gov with ImmunoGen, Inc. as lead sponsor.

NCT NCT00620607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00620607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Multiple Center Study of huC242-DM4 Given as an Intravenous Infusion Once Every Three Weeks to Patients With Metastatic Gastric or Gastroesophageal Junction Carcinomas
Lead sponsor
ImmunoGen, Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2007
Completion date
September 30, 2010
Enrollment
0 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic or local advanced ge junction cancer, metastatic or locally advanced gastric cancer, stomach neoplasms